Biotech M&A Outlook Boosted By AbbVie Deal, Says This RBC Analyst

By: via Benzinga
AbbVie Inc's (NYSE: ABBV) $21 billion deal Thursday to buy Pharmacyclics, Inc. (NASDAQ: PCYC) casts a bullish reflection on other ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.